Author: Fiona Craig

Asiamet Resources Limited (LSE:ARS) has initiated the debt financing process for the first phase of its BKM Copper Project, situated in Central Kalimantan, Indonesia. This development follows the successful completion of both an Optimised Feasibility Study and a review by an Independent Technical Expert—two critical components in de-risking the project. The company has now opened its project data room to prospective lenders, formally starting the due diligence phase. This move marks a pivotal step toward a final investment decision and reflects Asiamet’s strategy to advance the project while separately progressing discussions around offtake agreements and strategic partnerships. The update sends a clear message to stakeholders that the BKM Copper Project is poised for development.

About Asiamet Resources

Asiamet Resources Limited is a resource development company focused on advancing copper assets in Southeast Asia. The company’s flagship asset is the BKM Copper Project in Central Kalimantan, Indonesia. Listed on the AIM market under the ticker ARS, Asiamet is dedicated to developing high-quality base metal projects that align with global demand for copper in the energy transition.

Solvonis Therapeutics plc (LSE:SVNS) has successfully synthesized development candidates for its SVN-SDN-014 initiative, aimed at pioneering a novel class of treatments for post-traumatic stress disorder (PTSD). This accomplishment represents the third phase in the company’s seven-step translational development strategy, which is designed to improve therapeutic safety and foster pro-social behavior among PTSD patients. The milestone reflects Solvonis’s continued drive to meet critical mental health challenges. Upcoming stages in the development process will involve in-vitro assays and pre-clinical trials in animal models, bringing the program closer to potential regulatory submission.

About Solvonis Therapeutics

Headquartered in London, Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company committed to developing innovative therapies for addiction and mental health conditions. Traded on the London Stock Exchange, the company focuses on treating complex neuropsychiatric disorders such as Post-Traumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD). Leveraging a cost-effective model and a dual development approach, Solvonis is advancing both repurposed and proprietary drug candidates to address pressing unmet needs in mental health care.